Dongwha Pharm.Co.,Ltd (000020.KS)
KRW 6360.0
(-1.7%)
KRW 6360.0
(-1.7%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 184.12 Billion KRW | 1.73% |
| 2022 | 180.99 Billion KRW | 21.19% |
| 2021 | 149.34 Billion KRW | 7.7% |
| 2020 | 138.66 Billion KRW | 13.91% |
| 2019 | 121.73 Billion KRW | 5.03% |
| 2018 | 115.9 Billion KRW | 7.23% |
| 2017 | 108.08 Billion KRW | 4.76% |
| 2016 | 103.17 Billion KRW | 6.83% |
| 2015 | 96.57 Billion KRW | 1.44% |
| 2014 | 95.2 Billion KRW | -0.49% |
| 2013 | 95.67 Billion KRW | -3.14% |
| 2012 | 98.77 Billion KRW | -8.48% |
| 2011 | 107.93 Billion KRW | 15.07% |
| 2010 | 93.79 Billion KRW | 43.16% |
| 2009 | 65.51 Billion KRW | -37.71% |
| 2008 | 105.18 Billion KRW | 7.92% |
| 2007 | 97.46 Billion KRW | 34.08% |
| 2006 | 72.69 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 51.73 Billion KRW | -2.07% |
| 2024 Q1 | 52.82 Billion KRW | 17.27% |
| 2023 Q2 | 46.17 Billion KRW | -12.25% |
| 2023 Q1 | 52.62 Billion KRW | 14.64% |
| 2023 Q4 | 45.04 Billion KRW | 0.05% |
| 2023 Q3 | 45.02 Billion KRW | -2.5% |
| 2023 FY | 184.12 Billion KRW | 1.73% |
| 2022 Q1 | 44.66 Billion KRW | 9.36% |
| 2022 Q3 | 43.62 Billion KRW | -6.79% |
| 2022 Q4 | 45.9 Billion KRW | 5.22% |
| 2022 FY | 180.99 Billion KRW | 21.19% |
| 2022 Q2 | 46.8 Billion KRW | 4.79% |
| 2021 Q1 | 35.84 Billion KRW | -4.7% |
| 2021 FY | 149.34 Billion KRW | 7.7% |
| 2021 Q2 | 38.41 Billion KRW | 7.18% |
| 2021 Q3 | 34.25 Billion KRW | -10.83% |
| 2021 Q4 | 40.84 Billion KRW | 19.24% |
| 2020 Q4 | 37.6 Billion KRW | 9.36% |
| 2020 Q3 | 34.38 Billion KRW | -1.12% |
| 2020 Q2 | 34.77 Billion KRW | 9.05% |
| 2020 FY | 138.66 Billion KRW | 13.91% |
| 2020 Q1 | 31.89 Billion KRW | -10.97% |
| 2019 Q4 | 35.82 Billion KRW | 26.83% |
| 2019 Q2 | 27.61 Billion KRW | -8.1% |
| 2019 Q1 | 30.04 Billion KRW | 0.0% |
| 2019 FY | 121.73 Billion KRW | 5.03% |
| 2019 Q3 | 28.24 Billion KRW | 2.27% |
| 2018 Q4 | - KRW | -100.0% |
| 2018 FY | 115.9 Billion KRW | 7.23% |
| 2018 Q2 | 27.21 Billion KRW | -6.69% |
| 2018 Q1 | 29.16 Billion KRW | 10.55% |
| 2018 Q3 | 27.64 Billion KRW | 1.57% |
| 2017 Q3 | 27.18 Billion KRW | 0.46% |
| 2017 FY | 108.08 Billion KRW | 4.76% |
| 2017 Q4 | 26.38 Billion KRW | -2.96% |
| 2017 Q1 | 27.45 Billion KRW | 6.76% |
| 2017 Q2 | 27.05 Billion KRW | -1.45% |
| 2016 FY | 103.17 Billion KRW | 6.83% |
| 2016 Q1 | 26.99 Billion KRW | 0.33% |
| 2016 Q2 | 25.72 Billion KRW | -4.7% |
| 2016 Q3 | 24.73 Billion KRW | -3.85% |
| 2016 Q4 | 25.71 Billion KRW | 3.97% |
| 2015 Q1 | 23.57 Billion KRW | -19.9% |
| 2015 Q4 | 26.9 Billion KRW | 14.62% |
| 2015 Q3 | 23.47 Billion KRW | 3.77% |
| 2015 Q2 | 22.62 Billion KRW | -4.02% |
| 2015 FY | 96.57 Billion KRW | 1.44% |
| 2014 Q2 | 23.26 Billion KRW | 9.22% |
| 2014 Q1 | 21.29 Billion KRW | -5.54% |
| 2014 FY | 95.2 Billion KRW | -0.49% |
| 2014 Q4 | 29.42 Billion KRW | 38.72% |
| 2014 Q3 | 21.21 Billion KRW | -8.81% |
| 2013 Q3 | 21.7 Billion KRW | -11.51% |
| 2013 FY | 95.67 Billion KRW | -3.14% |
| 2013 Q1 | 26.9 Billion KRW | 13.53% |
| 2013 Q2 | 24.52 Billion KRW | -8.83% |
| 2013 Q4 | 22.54 Billion KRW | 3.9% |
| 2012 Q4 | 23.69 Billion KRW | -5.13% |
| 2012 Q1 | 24.22 Billion KRW | -3.49% |
| 2012 Q2 | 25.87 Billion KRW | 6.8% |
| 2012 FY | 98.77 Billion KRW | -8.48% |
| 2012 Q3 | 24.97 Billion KRW | -3.47% |
| 2011 FY | 107.93 Billion KRW | 15.07% |
| 2011 Q2 | 27.1 Billion KRW | -7.59% |
| 2011 Q4 | 25.1 Billion KRW | -4.89% |
| 2011 Q1 | 29.32 Billion KRW | 18.3% |
| 2011 Q3 | 26.39 Billion KRW | -2.61% |
| 2010 Q3 | 22.78 Billion KRW | -4.13% |
| 2010 Q4 | 24.79 Billion KRW | 8.81% |
| 2010 Q1 | 22.44 Billion KRW | 0.0% |
| 2010 FY | 93.79 Billion KRW | 43.16% |
| 2010 Q2 | 23.76 Billion KRW | 5.88% |
| 2009 Q2 | 24.3 Billion KRW | -22.42% |
| 2009 Q1 | 31.32 Billion KRW | 31.71% |
| 2009 FY | 65.51 Billion KRW | -37.71% |
| 2009 Q3 | 20 Billion KRW | -17.68% |
| 2008 FY | 105.18 Billion KRW | 7.92% |
| 2008 Q3 | 22.41 Billion KRW | -18.95% |
| 2008 Q4 | 23.78 Billion KRW | 6.08% |
| 2008 Q2 | 27.66 Billion KRW | -0.37% |
| 2008 Q1 | 27.76 Billion KRW | 20.83% |
| 2007 Q4 | 22.97 Billion KRW | -9.02% |
| 2007 FY | 97.46 Billion KRW | 34.08% |
| 2007 Q2 | 21.46 Billion KRW | 0.0% |
| 2007 Q3 | 25.25 Billion KRW | 17.63% |
| 2006 FY | 72.69 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -295.924% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 49.431% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 7.423% |
| HANDOK Inc. | 151.36 Billion KRW | -21.642% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -173.895% |
| Yuhan Corporation | 564.5 Billion KRW | 67.383% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 42.856% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -675.357% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 77.972% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -145.37% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 7.457% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -352.955% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -94.809% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -30.719% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -295.924% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -430.377% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -139.688% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 1628.561% |
| JW Holdings Corporation | 446.15 Billion KRW | 58.731% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 11.282% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 71.904% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 45.147% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -134.196% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -144.723% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -154.979% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -0.169% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -295.924% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 37.61% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 72.984% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 45.147% |
| Yuhan Corporation | 564.5 Billion KRW | 67.383% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 8.769% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -159.553% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -85.933% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 45.147% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -26.207% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -6.131% |
| CKD Bio Corp. | 5.01 Billion KRW | -3574.919% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 27.576% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -87.642% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -134.196% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 50.437% |
| Boryung Corporation | 333.26 Billion KRW | 44.752% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -267.914% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 7.457% |
| JW Lifescience Corporation | 51.32 Billion KRW | -258.743% |